SEC Form 4 · accession 0000899243-16-025726
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E. Hughes
Officer — President and CEO · Director
Period of report
Jul 22, 2016
Accepted (ET)
Jul 26, 2016 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3 | Jul 22, 2016 | M | 25,000 | $0.75 | A | 48,936 | D | |
| Common StockF1,F3 | Jul 22, 2016 | P | 5,000 | $3.0208 | A | 53,936 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.75 | Jul 22, 2016 | M | 25,000 | A | — | Dec 15, 2018 | Common Stock | 25,000 | 18,928 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.015 to 3.04, inclusive. The reporting person undertakes to provide to Zafgen, Inc., any security holder of Zafgen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- F2Fully vested.
- F3Includes 2,276 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan (the "Plan") on July 1, 2016, and 340 shares acquired under the Plan on January 1, 2016.